Advanced search
Publication Cover
Emerging Microbes & Infections Volume 1, 2012 - Issue 1
Submit an article Journal homepage
2,039
Views
57
CrossRef citations to date
0
Altmetric
Reviews

Avian influenza A H5N1 virus: a continuous threat to humans

Kelvin KW To1 State Key Laboratory for Emerging Infectious Diseases, The University of Hong Kong, Hong Kong Special Administrative Region, China;2 Research Centre of Infection and Immunology, The University of Hong Kong, Hong Kong Special Administrative Region, China;3 Department of Microbiology, The University of Hong Kong, Hong Kong Special Administrative Region, China
,
Kenneth HL Ng4 Department of Pathology, Tuen Mun Hospital, Hong Kong Special Administrative Region, China
,
Tak-Lun Que4 Department of Pathology, Tuen Mun Hospital, Hong Kong Special Administrative Region, China
,
Jacky MC Chan5 Department of Medicine and Geriatrics, Princess Margaret Hospital, Hong Kong Special Administrative Region, China
,
Kay-Yan Tsang5 Department of Medicine and Geriatrics, Princess Margaret Hospital, Hong Kong Special Administrative Region, China
,
Alan KL Tsang2 Research Centre of Infection and Immunology, The University of Hong Kong, Hong Kong Special Administrative Region, China;3 Department of Microbiology, The University of Hong Kong, Hong Kong Special Administrative Region, China
,
Honglin Chen1 State Key Laboratory for Emerging Infectious Diseases, The University of Hong Kong, Hong Kong Special Administrative Region, China;2 Research Centre of Infection and Immunology, The University of Hong Kong, Hong Kong Special Administrative Region, China;3 Department of Microbiology, The University of Hong Kong, Hong Kong Special Administrative Region, China
&
Kwok-Yung Yuen1 State Key Laboratory for Emerging Infectious Diseases, The University of Hong Kong, Hong Kong Special Administrative Region, China;2 Research Centre of Infection and Immunology, The University of Hong Kong, Hong Kong Special Administrative Region, China;3 Department of Microbiology, The University of Hong Kong, Hong Kong Special Administrative Region, ChinaCorrespondence[email protected]
 show all
Pages 1-12 | Received 06 Jan 2012, Accepted 25 Apr 2012, Published online: 25 Jan 2019

References

  • Yuen KY, Chan PK, Peiris M et al. Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet1998; 351: 467–471.
  • Cheng VC, Chan JF, Wen X et al. Infection of immunocompromised patients by avian H9N2 influenza A virus. J Infect2011; 62: 394–399.
  • Banks J, Speidel E, Alexander DJ. Characterisation of an avian influenza A virus isolated from a human—is an intermediate host necessary for the emergence of pandemic influenza viruses? Arch Virol1998; 143: 781–787.
  • Editorial team. Avian influenza A/(H7N2) outbreak in the United Kingdom. Euro Surveill2007; 12: E070531–E070532.
  • Tweed SA, Skowronski DM, David ST et al. Human illness from avian influenza H7N3, British Columbia. Emerg Infect Dis2004; 10: 2196–2199.
  • Arzey GG, Kirkland PD, Arzey KE et al. Influenza virus A (H10N7) in chickens and poultry abattoir workers, Australia. Emerg Infect Dis2012; 18: 814–816.
  • Cheng VC, To KK, Tse H, Hung IF, Yuen KY. Two years after pandemic influenza A/2009/H1N1: what have we learned? Clin Microbiol Rev2012; 25: 223–263.
  • World Health Organization. Cumulative number of confirmed human cases for avian influenza A(H5N1) reported to WHO, 2003–2012. Geneva: WHO, 2012. Available at http://www.who.int/influenza/human_animal_interface/EN_GIP_20120529CumulativeNumberH5N1cases.pdf (accessed 6 June 2012).
  • Abdel-Ghafar AN, Chotpitayasunondh T, Gao Z et al. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med2008; 358: 261–273.
  • World Health Organization. Antigenic and genetic characteristics of zoonotic influenza viruses and development of candidate vaccine viruses for pandemic preparedness. Geneva: WHO, 2012. Available at http://www.who.int/influenza/vaccines/virus/201202_h5_h9_vaccinevirusupdate.pdf (accessed 6 June 2012).
  • World Health Organization. Antigenic and genetic characteristics of zoonotic influenza viruses and development of candidate vaccine viruses for pandemic preparedness. Geneva: WHO, 2011. Available at http://www.who.int/influenza/resources/documents/2011_09_h5_h9_vaccinevirusupdate.pdf (accessed 6 June 2012).
  • World Health Organization. Updated unified nomenclature system for the highly pathogenic H5N1 avian influenza viruses. Geneva: WHO, 2011. Available at http://www.who.int/influenza/gisrs_laboratory/h5n1_nomenclature/en/index.html (accessed 6 June 2012).
  • Fiebig L, Soyka J, Buda S, Buchholz U, Dehnert M, Haas W. Avian influenza A(H5N1) in humans: new insights from a line list of World Health Organization confirmed cases, September 2006 to August 2010. Eur Surveill2011; 16: pii: 19941.
  • Kayali G, El-Shesheny R, Kutkat MA et al. Continuing threat of influenza (H5N1) virus circulation in Egypt. Emerg Infect Dis2011; 17: 2306–2308.
  • Wang TT, Parides MK, Palese P. Seroevidence for H5N1 influenza infections in humans: meta-analysis. Science2012; 335: 1463.
  • Murray EJ, Morse SS. Seasonal oscillation of human infection with influenza A/H5N1 in Egypt and Indonesia. PLoS ONE2011; 6: e24042.
  • To KK, Wong SS, Li IW et al. Concurrent comparison of epidemiology, clinical presentation and outcome between adult patients suffering from the pandemic influenza A (H1N1) 2009 virus and the seasonal influenza A virus infection. Postgrad Med J2010; 86: 515–521.
  • Zhang AJ, To KK, Tse H et al. High incidence of severe influenza among individuals over 50 years of age. Clin Vaccine Immunol2011; 18: 1918–1924.
  • Rutigliano JA, Morris MY, Yue W et al. Protective memory responses are modulated by priming events prior to challenge. J Virol2010; 84: 1047–1056.
  • Liem NT, Tung CV, Hien ND et al. Clinical features of human influenza A (H5N1) infection in Vietnam: 2004–2006. Clin Infect Dis2009; 48: 1639–1646.
  • Wan XF, Dong L, Lan Y et al. Indications that live poultry markets are a major source of human H5N1 influenza virus infection in China. J Virol2011; 85: 13432–13438.
  • Zhou L, Liao Q, Dong L et al. Risk factors for human illness with avian influenza A (H5N1) virus infection in China. J Infect Dis2009; 199: 1726–1734.
  • Indriani R, Samaan G, Gultom A et al. Environmental sampling for avian influenza virus A (H5N1) in live-bird markets, Indonesia. Emerg Infect Dis2010; 16: 1889–1895.
  • Wang H, Feng Z, Shu Y et al. Probable limited person-to-person transmission of highly pathogenic avian influenza A (H5N1) virus in China. Lancet2008; 371: 1427–1434.
  • Gambotto A, Barratt-Boyes SM, de Jong MD, Neumann G, Kawaoka Y. Human infection with highly pathogenic H5N1 influenza virus. Lancet2008; 371: 1464–1475.
  • Shinya K, Makino A, Tanaka H et al. Systemic dissemination of H5N1 influenza A viruses in ferrets and hamsters after direct intragastric inoculation. J Virol2011; 85: 4673–4678.
  • Harder TC, Teuffert J, Starick E et al. Highly pathogenic avian influenza virus (H5N1) in frozen duck carcasses, Germany, 2007. Emerg Infect Dis2009; 15: 272–279.
  • Imai M, Kawaoka Y. The role of receptor binding specificity in interspecies transmission of influenza viruses. Curr Opin Virol2012; 2: 160–167.
  • Gabriel G, Klingel K, Otte A et al. Differential use of importin-alpha isoforms governs cell tropism and host adaptation of influenza virus. Nat Commun2011; 2: 156.
  • Zimmermann P, Manz B, Haller O, Schwemmle M, Kochs G. The viral nucleoprotein determines Mx sensitivity of influenza A viruses. J Virol2011; 85: 8133–8140.
  • Miotto O, Heiny AT, Albrecht R et al. Complete-proteome mapping of human influenza A adaptive mutations: implications for human transmissibility of zoonotic strains. PLoS ONE2010; 5: e9025.
  • Tong S, Li Y, Rivailler P et al. A distinct lineage of influenza A virus from bats. Proc Natl Acad Sci USA2012; 109: 4269–4274.
  • Watanabe Y, Ibrahim MS, Suzuki Y, Ikuta K. The changing nature of avian influenza A virus (H5N1). Trends Microbiol2012; 20: 11–20.
  • Horimoto T, Kawaoka Y. Influenza: lessons from past pandemics, warnings from current incidents. Nat Rev Microbiol2005; 3: 591–600.
  • WHO/OIE/FAO H5N1 Evolution Working Group. Continued evolution of highly pathogenic avian influenza A (H5N1): updated nomenclature. Influenza Other Respi Viruses2012; 6: 1–5.
  • Buchy P, Fourment M, Mardy S et al. Molecular epidemiology of clade 1 influenza A viruses (H5N1), southern Indochina peninsula, 2004–2007. Emerg Infect Dis2009; 15: 1641–1644.
  • Dung Nguyen T, Vinh Nguyen T, Vijaykrishna D et al. Multiple sublineages of influenza A virus (H5N1), Vietnam, 2005–2007. Emerg Infect Dis2008; 14: 632–636.
  • Suwannakarn K, Amonsin A, Sasipreeyajan J et al. Molecular evolution of H5N1 in Thailand between 2004 and 2008. Infect Genet Evol2009; 9: 896–902.
  • Buchy P, Mardy S, Vong S et al. Influenza A/H5N1 virus infection in humans in Cambodia. J Clin Virol2007; 39: 164–168.
  • Le QM, Ito M, Muramoto Y et al. Pathogenicity of highly pathogenic avian H5N1 influenza A viruses isolated from humans between 2003 and 2008 in northern Vietnam. J Gen Virol2010; 91( Pt 10): 2485–2490.
  • Schmolke M, Manicassamy B, Pena L et al. Differential contribution of PB1-F2 to the virulence of highly pathogenic H5N1 influenza A virus in mammalian and avian species. PLoS Pathog2011; 7: e1002186.
  • Conenello GM, Zamarin D, Perrone LA, Tumpey T, Palese P. A single mutation in the PB1-F2 of H5N1 (HK/97) and 1918 influenza A viruses contributes to increased virulence. PLoS Pathog2007; 3: 1414–1421.
  • Govorkova EA, Ilyushina NA, Boltz DA, Douglas A, Yilmaz N, Webster RG. Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. Antimicrob Agents Chemother2007; 51: 1414–1424.
  • Nidom CA, Yamada S, Nidom RV et al. Genetic characterization of H5N1 influenza viruses isolated from chickens in Indonesia in 2010. Virus Genes2012; 44: 459–465.
  • Liu J, Xiao H, Lei F et al. Highly pathogenic H5N1 influenza virus infection in migratory birds. Science2005; 309: 1206.
  • Li Y, Shi J, Zhong G et al. Continued evolution of H5N1 influenza viruses in wild birds, domestic poultry, and humans in China from 2004 to 2009. J Virol2010; 84: 8389–8397.
  • Watanabe Y, Ibrahim MS, Ellakany HF et al. Acquisition of human-type receptor binding specificity by new H5N1 influenza virus sublineages during their emergence in birds in Egypt. PLoS Pathog2011; 7: e1002068.
  • Chen H, Li Y, Li Z et al. Properties and dissemination of H5N1 viruses isolated during an influenza outbreak in migratory waterfowl in western China. J Virol2006; 80: 5976–5983.
  • Neumann G, Chen H, Gao GF, Shu Y, Kawaoka Y. H5N1 influenza viruses: outbreaks and biological properties. Cell Res2010; 20: 51–61.
  • Le MT, Wertheim HF, Nguyen HD, et al. Influenza A H5N1 clade 2.3.4 virus with a different antiviral susceptibility profile replaced clade 1 virus in humans in northern Vietnam. PLoS ONE2008; 3: e3339.
  • Zhou JF, Zou SM, Li Z et al. Identification of dual receptor-binding specific strains of human H5N1 Viruses in China. Biomed Environ Sci2012; 25: 104–108.
  • Chen H, Smith GJ, Li KS et al. Establishment of multiple sublineages of H5N1 influenza virus in Asia: implications for pandemic control. Proc Natl Acad Sci USA2006; 103: 2845–2850.
  • Sakoda Y, Ito H, Uchida Y et al. Reintroduction of H5N1 highly pathogenic avian influenza virus by migratory water birds, causing poultry outbreaks in 2010–2011 winter season in Japan. J Gen Virol2012; 93( Pt 3): 541–550.
  • Islam MR, Haque ME, Giasuddin M et al. New introduction of clade 2.3.2.1 avian influenza virus (H5N1) into Bangladesh. Transbound Emerg Dis 2011 Dec 28. doi:10.1111/j.1865–1682.2011.01297.x.
  • WHO/FAO/OIE H5N1 Evolution Working Group. FAO-OIE-WHO technical update: current evolution of avian influenza H5N1 viruses. Geneva: WHO, 2012. Available at http://www.who.int/influenza/human_animal_interface/tripartite_notes_H5N1.pdf (accessed 6 June 2012).
  • Davis CT, Balish AL, O'Neill E et al. Detection and characterization of clade 7 high pathogenicity avian influenza H5N1 viruses in chickens seized at ports of entry and live poultry markets in Vietnam. Avian Dis2010; 54( 1 Suppl): 307–312.
  • Bao Y, Bolotov P, Dernovoy D et al. The influenza virus resource at the National Center for Biotechnology Information. J Virol2008; 82: 596–601.
  • Auewarakul P, Suptawiwat O, Kongchanagul A et al. An avian influenza H5N1 virus that binds to a human-type receptor. J Virol2007; 81: 9950–9955.
  • Medina RA, Garcia-Sastre A. Influenza A viruses: new research developments. Nat Rev Microbiol2011; 9: 590–603.
  • Gao Y, Zhang Y, Shinya K et al. Identification of amino acids in HA and PB2 critical for the transmission of H5N1 avian influenza viruses in a mammalian host. PLoS Pathog2009; 5: e1000709.
  • Stevens J, Blixt O, Chen LM, Donis RO, Paulson JC, Wilson IA. Recent avian H5N1 viruses exhibit increased propensity for acquiring human receptor specificity. J Mol Biol2008; 381: 1382–1394.
  • Yamada S, Suzuki Y, Suzuki T et al. Haemagglutinin mutations responsible for the binding of H5N1 influenza A viruses to human-type receptors. Nature2006; 444: 378–382.
  • Yamada S, Hatta M, Staker BL et al. Biological and structural characterization of a host-adapting amino acid in influenza virus. PLoS Pathog2010; 6: e1001034.
  • Ungchusak K, Auewarakul P, Dowell SF et al. Probable person-to-person transmission of avian influenza A (H5N1). N Engl J Med2005; 352: 333–340.
  • Huai Y, Xiang N, Zhou L et al. Incubation period for human cases of avian influenza A (H5N1) infection, China. Emerg Infect Dis2008; 14: 1819–1821.
  • Yu H, Gao Z, Feng Z et al. Clinical characteristics of 26 human cases of highly pathogenic avian influenza A (H5N1) virus infection in China. PLoS ONE2008; 3: e2985.
  • Shinya K, Ebina M, Yamada S, Ono M, Kasai N, Kawaoka Y. Avian flu: influenza virus receptors in the human airway. Nature2006; 440: 435–436.
  • Nicholls JM, Chan MC, Chan WY et al. Tropism of avian influenza A (H5N1) in the upper and lower respiratory tract. Nat Med2007; 13: 147–149.
  • van Riel D, den Bakker MA, Leijten LM et al. Seasonal and pandemic human influenza viruses attach better to human upper respiratory tract epithelium than avian influenza viruses. Am J Pathol2010; 176: 1614–1618.
  • Shinya K, Hatta M, Yamada S et al. Characterization of a human H5N1 influenza A virus isolated in 2003. J Virol2005; 79: 9926–9932.
  • Chandrasekaran A, Srinivasan A, Raman R et al. Glycan topology determines human adaptation of avian H5N1 virus hemagglutinin. Nat Biotechnol2008; 26: 107–113.
  • To KK, Hung IF, Li IW et al. Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection. Clin Infect Dis2010; 50: 850–859.
  • Schrauwen EJ, Herfst S, Leijten LM et al. The multi basic cleavage site in H5N1 virus is critical for systemic spread along the olfactory and hematogenous routes in ferrets. J Virol2012; 86: 3975–3984.
  • Zhang Z, Zhang J, Huang K et al. Systemic infection of avian influenza A virus H5N1 subtype in humans. Hum Pathol2009; 40: 735–739.
  • Gu J, Xie Z, Gao Z et al. H5N1 infection of the respiratory tract and beyond: a molecular pathology study. Lancet2007; 370: 1137–1145.
  • Zhou JJ, Fang DY, Fu J et al. Infection and replication of avian influenza H5N1 virus in an infected human. Virus Genes2009; 39: 76–80.
  • de Jong MD, Bach VC, Phan TQ et al. Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma. N Engl J Med2005; 352: 686–691.
  • Li IW, Chan KH, To KW et al. Differential susceptibility of different cell lines to swine-origin influenza A H1N1, seasonal human influenza A H1N1, and avian influenza A H5N1 viruses. J Clin Virol2009; 46: 325–330.
  • Shinya K, Makino A, Hatta M et al. Subclinical brain injury caused by H5N1 influenza virus infection. J Virol2011; 85: 5202–5207.
  • Jang H, Boltz D, Sturm-Ramirez K et al. Highly pathogenic H5N1 influenza virus can enter the central nervous system and induce neuroinflammation and neurodegeneration. Proc Natl Acad Sci USA2009; 106: 14063–14068.
  • Woo PC, Tung ET, Chan KH, Lau CC, Lau SK, Yuen KY. Cytokine profiles induced by the novel swine-origin influenza A/H1N1 virus: implications for treatment strategies. J Infect Dis2010; 201: 346–353.
  • Cilloniz C, Shinya K, Peng X et al. Lethal influenza virus infection in macaques is associated with early dysregulation of inflammatory related genes. PLoS Pathog2009; 5: e1000604.
  • Zeng H, Pappas C, Belser JA et al. Human pulmonary microvascular endothelial cells support productive replication of highly pathogenic avian influenza viruses: possible involvement in the pathogenesis of human H5N1 virus infection. J Virol2012; 86: 667–678.
  • Schmolke M, Viemann D, Roth J, Ludwig S. Essential impact of NF-kappaB signaling on the H5N1 influenza A virus-induced transcriptome. J Immunol2009; 183: 5180–5189.
  • Li C, Bankhead A 3rd, Eisfeld AJ et al. Host regulatory network response to infection with highly pathogenic H5N1 avian influenza virus. J Virol2011; 85: 10955–10967.
  • Ramos I, Bernal-Rubio D, Durham N et al. Effects of receptor binding specificity of avian influenza virus on the human innate immune response. J Virol2011; 85: 4421–4431.
  • Cilloniz C, Pantin-Jackwood MJ, Ni C et al. Lethal dissemination of H5N1 influenza virus is associated with dysregulation of inflammation and lipoxin signaling in a mouse model of infection. J Virol2010; 84: 7613–7624.
  • Soepandi PZ, Burhan E, Mangunnegoro H et al. Clinical course of avian influenza A(H5N1) in patients at the Persahabatan Hospital, Jakarta, Indonesia, 2005–2008. Chest2010; 138: 665–673.
  • Brundage JF. Interactions between influenza and bacterial respiratory pathogens: implications for pandemic preparedness. Lancet Infect Dis2006; 6: 303–312.
  • To KK, Chan KH, Fung YF, Yuen KY, Ho PL. Azithromycin treatment failure in macrolide-resistant Mycoplasma pneumoniae pneumonia. Eur Respir J2010; 36: 969–971.
  • de Jong MD, Simmons CP, Thanh TT et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med2006; 12: 1203–1207.
  • Chen H, Wen X, To KK et al. Quasispecies of the D225G substitution in the hemagglutinin of pandemic influenza A(H1N1) 2009 virus from patients with severe disease in Hong Kong, China. J Infect Dis2010; 201: 1517–1521.
  • Zheng B, Chan KH, Zhang AJ et al. D225G mutation in hemagglutinin of pandemic influenza H1N1 (2009) virus enhances virulence in mice. Exp Biol Med (Maywood)2010; 235: 981–988.
  • Zhou J, To KK, Dong H et al. A functional variation in CD55 increases the severity of 2009 pandemic H1N1 influenza A virus infection. J Infect Dis2012; 206: 495–503
  • Sakai-Tagawa Y, Ozawa M, Tamura D et al. Sensitivity of influenza rapid diagnostic tests to H5N1 and 2009 pandemic H1N1 viruses. J Clin Microbiol2010; 48: 2872–2877.
  • Chen W, He B, Li C et al. Real-time RT-PCR for H5N1 avian influenza A virus detection. J Med Virol2007; 56( Pt 5): 603–607.
  • Rowe T, Abernathy RA, Hu-Primmer J et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol1999; 37: 937–943.
  • Buchy P, Vong S, Chu S et al. Kinetics of neutralizing antibodies in patients naturally infected by H5N1 virus. PLoS ONE2010; 5: e10864.
  • Lan Y, Zhang Y, Dong L et al. A comprehensive surveillance of adamantane resistance among human influenza A virus isolated from mainland China between 1956 and 2009. Antivir Ther2010; 15: 853–859.
  • Cheung CL, Rayner JM, Smith GJ et al. Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. J Infect Dis2006; 193: 1626–1629.
  • Pielak RM, Schnell JR, Chou JJ. Mechanism of drug inhibition and drug resistance of influenza A M2 channel. Proc Natl Acad Sci USA2009; 106: 7379–7384.
  • Adisasmito W, Chan PK, Lee N et al. Effectiveness of antiviral treatment in human influenza A(H5N1) infections: analysis of a Global Patient Registry. J Infect Dis2010; 202: 1154–1160.
  • Stittelaar KJ, Tisdale M, van Amerongen G et al. Evaluation of intravenous zanamivir against experimental influenza A (H5N1) virus infection in cynomolgus macaques. Antiviral Res2008; 80: 225–228.
  • Kiso M, Kubo S, Ozawa M et al. Efficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza viruses. PLoS Pathog2010; 6: e1000786.
  • Boltz DA, Ilyushina NA, Arnold CS, Babu YS, Webster RG, Govorkova EA. Intramuscularly administered neuraminidase inhibitor peramivir is effective against lethal H5N1 influenza virus in mice. Antivir Res2008; 80: 150–157.
  • McKimm-Breschkin JL, Selleck PW, Usman TB, Johnson MA. Reduced sensitivity of influenza A (H5N1) to oseltamivir. Emerg Infect Dis2007; 13: 1354–1357.
  • Naughtin M, Dyason JC, Mardy S, Sorn S, von Itzstein M, Buchy P. Neuraminidase inhibitor sensitivity and receptor-binding specificity of Cambodian clade 1 highly pathogenic H5N1 influenza virus. Antimicrob Agents Chemother2011; 55: 2004–2010.
  • de Jong MD, Tran TT, Truong HK et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med2005; 353: 2667–2672.
  • Kiso M, Ozawa M, Le MT et al. Effect of an asparagine-to-serine mutation at position 294 in neuraminidase on the pathogenicity of highly pathogenic H5N1 influenza A virus. J Virol2011; 85: 4667–4672.
  • Boltz DA, Douangngeun B, Phommachanh P et al. Emergence of H5N1 avian influenza viruses with reduced sensitivity to neuraminidase inhibitors and novel reassortants in Lao People's Democratic Republic. J Gen Virol2010; 91( Pt 4): 949–959.
  • Collins PJ, Haire LF, Lin YP et al. Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature2008; 453: 1258–1261.
  • Zhao G, Zhong L, Lu X, et al. Characterisation of a highly pathogenic H5N1 clade 2.3.2 influenza virus isolated from swans in Shanghai, China. Virus Genes2012; 44: 55–62.
  • Jefferson T, Jones MA, Doshi P et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev2012; 1: CD008965.
  • Kao RY, Yang D, Lau LS et al. Identification of influenza A nucleoprotein as an antiviral target. Nat Biotechnol2010; 28: 600–605.
  • Kumaki Y, Day CW, Smee DF, Morrey JD, Barnard DL. In vitro and in vivo efficacy of fluorodeoxycytidine analogs against highly pathogenic avian influenza H5N1, seasonal, and pandemic H1N1 virus infections. Antiviral Res2011; 92: 329–340.
  • Kiso M, Takahashi K, Sakai-Tagawa Y et al. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc Natl Acad Sci USA2010; 107: 882–887.
  • Triana-Baltzer GB, Gubareva LV, Klimov AI et al. Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein. PLoS ONE2009; 4: e7838.
  • Belser JA, Lu X, Szretter KJ et al. DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection. J Infect Dis2007; 196: 1493–1499.
  • Nicol MQ, Ligertwood Y, Bacon MN, Dutia BM, Nash AA. A novel family of peptides with potent activity against influenza A viruses. J Gen Virol2012; 93( Pt 5): 980–986.
  • Zheng BJ, Chan KW, Lin YP et al. Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc Natl Acad Sci USA2008; 105: 8091–8096.
  • Henter JI, Chow CB, Leung CW, Lau YL. Cytotoxic therapy for severe avian influenza A (H5N1) infection. Lancet2006; 367: 870–873.
  • Henter JI, Palmkvist-Kaijser K, Holzgraefe B, Bryceson YT, Palmer K. Cytotoxic therapy for severe swine flu A/H1N1. Lancet2010; 376: 2116.
  • Van Hoeven N, Belser JA, Szretter KJ et al. Pathogenesis of 1918 pandemic and H5N1 influenza virus infections in a guinea pig model: antiviral potential of exogenous alpha interferon to reduce virus shedding. J Virol2009; 83: 2851–2861.
  • Haasbach E, Pauli EK, Spranger R et al. Antiviral activity of the proteasome inhibitor VL-01 against influenza A viruses. Antiviral Res2011; 91: 304–313.
  • Hung IF, To KK, Lee CK et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis2011; 52: 447–456.
  • Prabhu N, Prabakaran M, Ho HT et al. Monoclonal antibodies against the fusion peptide of hemagglutinin protect mice from lethal influenza A virus H5N1 infection. J Virol2009; 83: 2553–2562.
  • Yupiana Y, de Vlas SJ, Adnan NM, Richardus JH. Risk factors of poultry outbreaks and human cases of H5N1 avian influenza virus infection in West Java Province, Indonesia. Int J Infect Dis2010; 14: e800–e805.
  • Guan Y, Chen H, Li K et al. A model to control the epidemic of H5N1 influenza at the source. BMC Infect Dis2007; 7: 132.
  • Henning J, Wibawa H, Morton J, Usman TB, Junaidi A, Meers J. Scavenging ducks and transmission of highly pathogenic avian influenza, Java, Indonesia. Emerg Infect Dis2010; 16: 1244–1250.
  • Paul M, Wongnarkpet S, Gasqui P et al. Risk factors for highly pathogenic avian influenza (HPAI) H5N1 infection in backyard chicken farms, Thailand. Acta Trop2011; 118: 209–216.
  • Henning KA, Henning J, Morton J, Long NT, Ha NT, Meers J. Farm- and flock-level risk factors associated with highly pathogenic avian influenza outbreaks on small holder duck and chicken farms in the Mekong Delta of Viet Nam. Prev Vet Med2009; 91: 179–188.
  • Wu WL, Chen Y, Wang P et al. Antigenic profile of avian H5N1 viruses in Asia from 2002 to 2007. J Virol2008; 82: 1798–1807.
  • Normile D. Avian influenza. Warning of H5N1 resurgence surprises community. Science2011; 333: 1369.
  • Sakoda Y, Ito H, Uchida Y et al. Reintroduction of H5N1 highly pathogenic avian influenza virus by migratory water birds, causing poultry outbreaks in the 2010–2011 winter season in Japan. J Gen Virol2012; 93( Pt 3): 541–550.
  • Ehrlich HJ, Muller M, Oh HM et al. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med2008; 358: 2573–2584.
  • Khurana S, Wu J, Verma N et al. H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans. J Virol2011; 85: 10945–10954.
  • Langley JM, Risi G, Caldwell M et al. Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study. J Infect Dis2011; 203: 1729–1738.
  • Galli G, Hancock K, Hoschler K et al. Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc Natl Acad Sci USA2009; 106: 7962–7967.
  • Patel SM, Atmar RL, El Sahly HM, Cate TR, Keitel WA. A phase I evaluation of inactivated influenza A/H5N1 vaccine administered by the intradermal or the intramuscular route. Vaccine2010; 28: 3025–3029.
  • Stephenson I, Nicholson KG, Hoschler K et al. Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1. N Engl J Med2008; 359: 1631–1633.
  • Lyall J, Irvine RM, Sherman A et al. Suppression of avian influenza transmission in genetically modified chickens. Science2011; 331: 223–226.
  • Steel J, Lowen AC, Mubareka S, Palese P. Transmission of influenza virus in a mammalian host is increased by PB2 amino acids 627K or 627E/701N. PLoS Pathog2009; 5: e1000252.
  • Belser JA, Katz JM, Tumpey TM. The ferret as a model organism to study influenza A virus infection. Dis Model Mech2011; 4: 575–579.
  • Gustin KM, Belser JA, Wadford DA, et al. Influenza virus aerosol exposure and analytical system for ferrets. Proc Natl Acad Sci USA2011; 108: 8432–8437.
  • Chen LM, Blixt O, Stevens J et al. In vitro evolution of H5N1 avian influenza virus toward human-type receptor specificity. Virology2012; 422: 105–113.
  • Imai M, Watanabe T, Hatta M et al. Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature2012; 486: 420–428.
  • Herfst S, Schrauwen EJ, Linster M et al. Airborne transmission of influenza A/H5N1 virus between ferrets. Science2012; 336: 1534–1541.
  • World Health Organization. Public health, influenza experts agree H5N1 research critical, but extend delay. Geneva: WHO, 2012. Available at: http://www.who.int/mediacentre/news/releases/2012/h5n1_research_20120217/en/index.html (accessed 6 June 2012).
  • Palese P, Wang TT. H5N1 influenza viruses: Facts, not fear. Proc Natl Acad Sci USA2012; 109: 2211–2213.
  • Cohen J, Malakoff D. Avian influenza. On second thought, flu papers get go-ahead. Science2012; 336: 19–20.
  • Enserink M. Infectious diseases. Controversial studies give a deadly flu virus wings. Science2011; 334: 1192–1193.
  • Siegel JD, Rhinehart E, Jackson M, Chiarello L, Practices HCIC. 2007 guideline for isolation precautions: preventing transmission of infectious agents in health care settings. Am J Infect Control2007; 35: S65–S164.
  • Carrel M, Wan XF, Nguyen T, Emch M. Genetic Variation of highly pathogenic H5N1 avian influenza viruses in vietnam shows both species-specific and spatiotemporal associations. Avian Dis2011; 55: 659–666.
  • Fusaro A, Nelson MI, Joannis T et al. Evolutionary dynamics of multiple sublineages of H5N1 influenza viruses in Nigeria from 2006 to 2008. J Virol2010; 84: 3239–3247.
  • Cattoli G, Fusaro A, Monne I et al. Evidence for differing evolutionary dynamics of A/H5N1 viruses among countries applying or not applying avian influenza vaccination in poultry. Vaccine2011; 29: 9368–9375.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.